1Zhang S, Zhang M, Wu W, et al. Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer. Antibody Therapeutics. 21 Sep 2018; 1(2):45-53. https://doi.org/10.1093/abt/tby005
2Hoy SM. Sintilimab: First Global Approval. Drugs 2019 Feb;79(3):341-346. doi: 10.1007/s40265-019-1066-z.